/Idex%20Corporation%20logo%20and%20chart%20data-by%20Piotr%20Swat%20via%20Shutterstock.jpg)
Northbrook, Illinois-based IDEX Corporation (IEX) is an applied solutions company specializing in a range of applications such as fluid and metering technologies, health and science technologies, and fire, safety, and other products. With a market cap of $12.1 billion, IDEX's operations span the Americas, Europe, and the Indo-Pacific.
Companies worth $10 billion or more are generally referred to as “large-cap stocks.” IEX fits right into that category, with its market cap exceeding this threshold, reflecting its substantial size and influence in the industrial sector.
Despite its notable strengths, IDEX’s stock prices have plummeted 32.4% from its 52-week high of $238.22 touched on Nov. 6, 2024. Meanwhile, the stock has dropped 8% over the past three months, notably underperforming the Nasdaq Composite’s ($NASX) 15.8% surge during the same time frame.
IDEX’s performance looks much more grim over the longer term. The stock has plunged 23.1% on a YTD basis and 23.5% over the past 52 weeks, significantly underperforming the Nasdaq’s 17.2% gains in 2025 and 25.6% surge over the past year.
Further, the stock has traded consistently below its 200-day moving average since early February and mostly below its 50-day moving average since mid-December 2024, with some fluctuations, underscoring its bearish momentum.
Despite delivering better-than-expected results, IDEX’s stock prices dropped 11.3% in a single trading session following the release of its Q2 results on Jul. 30. Driven by a slight uptick in organic revenues and contributions from acquired businesses, the company achieved record sales during the quarter. Its net sales came in at $865.4 million, up 7.2% year-over-year, beating the Street’s expectations by almost 1%. Further, the company delivered an adjusted EPS of $2.07, surpassing the consensus estimates by 3.5%. However, the company’s full-year guidance didn’t match Street’s expectations, triggering the sell-off.
When compared to its peer, IDEX’s performance looks even more concerning. IDEX has significantly lagged behind AMETEK, Inc.’s (AME) 4.2% uptick in 2025 and 9.1% gains over the past 52 weeks.
Nonetheless, among the 13 analysts covering the IEX stock, the consensus rating is a “Moderate Buy.” Its mean price target of $192.82 suggests a 19.7% upside potential.
